


Amended Claims

1. (currently amended) A method of preventing or inhibiting solid tumor melanoma growth, lung carcinoma growth, or hypercalcemia in a mammal, wherein:

the method comprises comprising administering to a mammal in need thereof a therapeutically effective amount of:

a compound or pharmaceutically acceptable salt thereof, and
a chemotherapeutic agent;

the compound corresponds in structure to [[of]] the formula:




X and Y are independently selected the same or different halo [[group]];






R is H or lower alkyl; and ~~pharmaceutically acceptable salts thereof; together with a~~
~~the~~ chemotherapeutic agent is selected from the group consisting of cyclophosphamide, ~~methotrexate~~ methotrexate, fluorouracil, paclitaxel, mitomycin, leuprolide, leucovorin, carboplatin, dacarbazine, vinblastine, etoposide, ifosfamide, dactinomycin, and carmustine.




Claim 2. (canceled).

3. (previously presented) A method according to claim 1 wherein the compound is selected from the group consisting of:



Amendment D
U.S. Appl. 10/016,146
April 1, 2005






Claim 4. (canceled).

5. (currently amended) A method of preventing or inhibiting solid tumor melanoma growth, lung carcinoma growth, or hypercalcemia in a mammal, wherein:

the method comprises comprising administering to a mammal in need thereof a therapeutically effective amount of:

a compound or pharmaceutically acceptable salt thereof, and
a chemotherapeutic agent;

the compound corresponds in structure to [[of]] the formula:






X and Y are independently selected the same or different halo [[group]]; ;






R is H or lower alkyl; ~~and or a pharmaceutically acceptable salt thereof, together with a~~


the chemotherapeutic agent is selected from the group consisting of cyclophosphamide, methotrexate methotrexate, fluorouracil, paclitaxel, mitomycin, leuprolide, leucovorin, carboplatin, dacarbazine, vinblastine, etoposide, ifosfamide, dactinomycin, and carmustine.

Claim 6. (canceled).

7. (previously presented) A method according to claim 5 wherein the compound is selected from the group consisting of:








8. (canceled).

9. (currently amended) A pharmaceutical composition, wherein:
the composition comprises: ~~comprising~~

a therapeutically effective amount of a compound (or a pharmaceutically acceptable salt thereof) and a chemotherapeutic agent; and
a pharmaceutically acceptable carrier;






the compound corresponds in structure to [[of]] the formula:













X and Y are independently selected ~~the same or different~~ halo [[group]];
R is H or lower alkyl; and ~~or a pharmaceutically acceptable salt thereof,~~
a chemotherapeutic agent selected from the group consisting of cyclophosphamide,
~~methotrexate~~ methotrexate, fluorouracil, paclitaxel, mitomycin, leuprolide, leucovorin,
carboplatin, dacarbazine, vinblastine, etoposide, ifosfamide, dactinomycin, and carmustine; and
~~a pharmaceutically acceptable carrier.~~




Claims 10-13 (canceled).

14. (currently amended) A pharmaceutical composition as set forth in claim 9, wherein
~~the composition comprises a therapeutically effective amount of a~~ compound is selected from
the group consisting of:









Please add the following new claims:

15. (new) A method according to claim 1, wherein melanoma growth is inhibited or prevented.

16. (new) A method according to claim 1, wherein lung carcinoma growth is inhibited or prevented.

17. (new) A method according to claim 1, wherein hypercalcemia is inhibited or prevented.

18. (new) A method according to claim 5, wherein melanoma growth is inhibited or prevented.


19. (new) A method according to claim 5, wherein lung carcinoma growth is inhibited or prevented.

20. (new) A method according to claim 5, wherein hypercalcemia is inhibited or prevented.

21. (new) A method according to claim 1, wherein the chemotherapeutic agent is cyclophosphamide.

22. (new) A method according to claim 5, wherein the chemotherapeutic agent is cyclophosphamide.

23. (new) A method according to claim 5, wherein the compound is:



24. (new) A method according to claim 23, wherein the chemotherapeutic agent is cyclophosphamide.

25. (new) A method according to claim 24, wherein melanoma growth is inhibited or prevented.

26. (new) A method according to claim 24, wherein lung carcinoma growth is inhibited or prevented.